Grundlæggende statistik
| LEI | 529900TIWO8H06FQC983 |
| CIK | 1326205 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to IGC Pharma, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specified i |
|
| April 20, 2026 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 1, 2026, by and between IGC PHARMA, INC., a Maryland corporation, with its address at 10224 Falls Road, Potomac, Maryland 20854 (the “Company”), and Vanquish Funding Group Inc., a Virginia corporation, with its address at 1800 Diagonal Road, Suite 623, Alexandria VA 22314 (the “Buyer” |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2026 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 20, 2026 |
Exhibit 10.2 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN |
|
| April 20, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 10, 2026, by and between IGC PHARMA, INC., a Maryland corporation, with its address at 10224 Falls Road, Potomac, Maryland 20854 (the “Company”), and FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company, with its address at 1040 First Avenue, Suite 190, New Y |
|
| April 20, 2026 |
THE ISSUE PRICE OF THIS NOTE IS $238,050.00 THE ORIGINAL ISSUE DISCOUNT IS $31,050.00 Exhibit 10.4 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 30, 2026 |
Exhibit 99.1 IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness POTOMAC, MARYLAND - March 30, 2026 - IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced a strategic 12-part national media partnership with New to The Street, a |
|
| March 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KT ☐ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☒ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from April 1, 2025 to December 31, 2025 Commission file number: 001-32830 IGC PHARMA, INC. (Exact Name of Registr |
|
| March 18, 2026 |
The table below lists our subsidiaries. Exhibit 21.1 The table below lists our subsidiaries. Subsidiaries Ultimate holding company Jurisdiction of Incorporation Percentage of holding as of December 31, 2025 Percentage of holding as of March 31, 2025 IGCare, LLC IGC Maryland, USA - 100 IGC Pharma, LLC IGC Delaware, USA 100 100 HH Processors, LLC (formerly Holi Hemp, LLC) IGC Maryland, USA 100 100 Sunday Seltzer, LLC IGC Maryland, USA - 1 |
|
| March 12, 2026 |
Exhibit 10.3 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
|
| March 12, 2026 |
THE ISSUE PRICE OF THIS NOTE IS $353,050.00 THE ORIGINAL ISSUE DISCOUNT IS $46,050.00 Exhibit 10.2 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN |
|
| March 12, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 5, 2026, by and between IGC PHARMA, INC., a Maryland corporation, with its address at 10224 Falls Road, Potomac, Maryland 20854 (the “Company”), and Vanquish Funding Group Inc., a Virginia corporation, with its address at 1800 Diagonal Road, Suite 623, Alexandria VA 22314 (the “Buyer” |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2026 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 6, 2026 |
779,997 Shares of Common Stock IGC Pharma, Inc. Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-276330 PROSPECTUS SUPPLEMENT (To the Prospectus dated January 8, 2024) 779,997 Shares of Common Stock IGC Pharma, Inc. Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 779,997 shares of our common stock, par value $0.0001 per share (“Common Stock”), directly to the investors without a placemen |
|
| January 6, 2026 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT IGC Pharma, Inc. 10224 Falls Road Potomac, Maryland 20854 Ladies and Gentlemen: The Investor (the “Investor”) hereby confirms its agreement (this “Agreement”) with IGC Pharma, Inc., a Maryland corporation (the “Company”), as follows: 1. Purchase and Sale. The Company and the Investor agree that the Investor will purchase from the Company, and the Company will is |
|
| January 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2025 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 15, 2025 |
Exhibit 3.1 Vice President & CCO President & CEO Acknowledgment Number: 1000362015152459 Filing Date and Time: 11/25/2025 7:03:52 AM Authentication Number: Cx3vtZYZjkeOSwaRJnYpug Page 1 of 2 |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 4, 2025 |
December 4, 2025 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory, Esq. Division of Corporation Finance Re: IGC Pharma, Inc. Registration Statement on Form S-3 (No. 333-291567) Ladies and Gentlemen: On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration S |
|
| December 3, 2025 |
As filed with the U.S. Securities and Exchange Commission on December 3, 2025 As filed with the U.S. Securities and Exchange Commission on December 3, 2025 Registration No. 333-291567 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IGC PHARMA, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or other jurisdiction of (I.R.S. Employ |
|
| November 17, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 IGC Pharma, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, par va |
|
| November 17, 2025 |
As filed with the U.S. Securities and Exchange Commission on November XX, 2025 As filed with the U.S. Securities and Exchange Commission on November XX, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IGC PHARMA, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or other jurisdiction of (I.R.S. Employer incorporation or orga |
|
| November 14, 2025 |
As filed with the Securities and Exchange Commission on November 14, 2025 As filed with the Securities and Exchange Commission on November 14, 2025 Registration No. |
|
| November 14, 2025 |
CALCULATION OF FILING FEE TABLES IGC Pharma, Inc Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 IGC Pharma, Inc Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| November 14, 2025 |
IGC Pharma Inc UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 IGC Pharma Inc UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1 — Transaction Overview On September 29, 2025, Holi Hemp LLC (“HHP”), a wholly owned subsidiary of IGC Pharma, Inc. (the “Company”), completed the disposition of certain manufacturing equipment, leasehold assets, and inventory located at its Vancouver, Washington facility (the “Vancouver Facility”) pu |
|
| November 14, 2025 |
IGC PHARMA, INC. 2018 OMNIBUS INCENTIVE PLAN Notice of restricted stock unit award Exhibit 10.2 IGC PHARMA, INC. 2018 OMNIBUS INCENTIVE PLAN Notice of restricted stock unit award Participant Name and Address: You (the “Participant”) have been granted restricted stock units (“Restricted Stock Units” or “RSUs”), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the “Notice”), the IGC Pharma, Inc. 2018 Omnibus Incentive Plan the “Plan”) and the Rest |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specifi |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 14, 2025 |
IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders Exhibit 99.1 IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders POTOMAC, MARYLAND - October 10, 2025 - IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced results from its Annual Meeting of Stockholders scheduled for and convened |
|
| October 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2025 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 1, 2025 |
SALE OF ASSETS AND MANUFACTURING AGREEMENT Exhibit 10.1 SALE OF ASSETS AND MANUFACTURING AGREEMENT This Sale of Assets and Manufacturing Agreement (“Agreement”) is entered into as of September 29, 2025 (the “Effective Date”) subject to Closing (“Closing”), by and between: · Holi Hemp LLC, dba HH Processors, a Maryland limited liability company and wholly owned subsidiary of IGC Pharma Inc., a Maryland corporation listed on the NYSE America |
|
| September 19, 2025 |
Up to $11,309,229 IGC Pharma, Inc. Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To the Prospectus effective January 8, 2024) Registration No. |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 14, 2025 |
Extension of Master Loan Agreement between IGC Pharma, Inc. and O-Bank, CO., LTD. Exhibit 10.1 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specified in |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 24, 2025 |
July 24, 2025 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards, Esq. Division of Corporation Finance Re: IGC Pharma, Inc. Registration Statement on Form S-3 (No. 333-288785) Ladies and Gentlemen: On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration St |
|
| July 23, 2025 |
July 23, 2025 Ram Mukunda President and Chief Executive Officer IGC Pharma, Inc. 10224 Falls Road Potomac, Maryland 20854 Re: IGC Pharma, Inc. Registration Statement on Form S-3 Filed July 18, 2025 File No. 333-288785 Dear Ram Mukunda: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accelerati |
|
| July 18, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) IGC Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Title of Each Class of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equit |
|
| July 18, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 16, 2025 As filed with the U.S. Securities and Exchange Commission on July 16, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IGC PHARMA, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or other jurisdiction of (I.R.S. Employer incorporation or organiza |
|
| June 27, 2025 |
Subsidiaries of India Globalization Capital, Inc. Exhibit 21.1 The table below lists our subsidiaries. Subsidiaries Ultimate holding company Jurisdiction of Incorporation Percentage of holding as of March 31, 2025 Percentage of holding as of March 31, 2024 IGCare, LLC IGC Maryland, USA 100 100 IGC Pharma, LLC IGC Colorado, USA 100 100 HH Processors, LLC (formerly Holi Hemp, LLC) IGC Maryland, USA 100 100 Sunday Seltzer, LLC IGC Maryland, USA 100 |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Fiscal Year Ended March 31, 2025. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-32830 IGC PHARMA, INC. (Exact Name of Re |
|
| June 27, 2025 |
Exhibit 19.1 INSIDER TRADING AND REPORTING POLICY IGC PHARMA, INC. (formerly known as India Globalization Capital, Inc.) (NYSE: IGC) Adopted 2005 Amended , 2025 IGC Pharma, Inc. and its subsidiaries and related corporations and partnerships (collectively, “IGC” or the “Corporation”) are always firmly committed to the principles of fair and open markets for publicly traded securities. This policy s |
|
| June 17, 2025 |
Exhibit 99.1 Date: June 16, 2025 NYSEAmerican: IGC 1 NYSE AMERICAN: IGC - Service to humanity - Safe Harbor The information presented in these slides includes forward - looking statements regarding the business prospects of IGC Pharma, Inc . ("IGC" or the "Company") . These forward - looking statements are based on management's current expectations as of the date of this presentation and are subje |
|
| June 17, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specifie |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specifi |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 27, 2024 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT WITH MORAN GLOBAL STRATEGIES INC. STOCK PURCHASE AGREEMENT (this “Agreement”) dated as signed by and between IGC Pharma, Inc., a Maryland corporation (the “Company”), and Investor as identified in Exhibit B (the “Investor”). WHEREAS, the Investor desires to purchase from the Company, and the Company desires to sell and issue to the Investor, shares in IGC (the |
|
| August 27, 2024 |
IGC Announces Results of its 2024 Annual Stockholders Meeting Exhibit 99.1 IGC Announces Results of its 2024 Annual Stockholders Meeting POTOMAC, MD. (Business Wire) August 26, 2024 / IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the “Annual Meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with |
|
| August 27, 2024 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* IGC Pharma Inc. (IGC) (Name of Issuer) Common Stock, , par value $0.0001 per share (Title of Class of Securities) 45408X308 (CUSIP Number) Loo See Yuen The Center, Unit 5106-7 51st Floor 99 Queen's Road Central Central, Hong Kong +65 9792 8758 (Name, A |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specified in |
|
| August 7, 2024 |
August 7, 2024 Loo See Yuen Director Bradbury Strategic Investment Fund A The Center, Unit 5106-7 51st Floor 99 Queen's Road Central Central, Hong Kong Re: Bradbury Strategic Investment Fund A IGC Pharma, Inc. |
|
| August 2, 2024 |
Exhibit 10.1 |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 24, 2024 |
Subsidiaries of India Globalization Capital, Inc. Exhibit 21.1 The table below lists our subsidiaries. Subsidiaries Immediate holding company Jurisdiction of Incorporation Percentage of holding as of March 31, 2024 Percentage of holding as of March 31, 2023 IGCare, LLC IGC Maryland, USA 100 100 IGC Pharma, LLC IGC Colorado, USA 100 100 HH Processors, LLC (formerly Holi Hemp, LLC) IGC Maryland, USA 100 100 Sunday Seltzer, LLC IGC Maryland, USA 100 |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Fiscal Year Ended March 31, 2024. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-32830 IGC PHARMA, INC. (Exact Name of Re |
|
| June 24, 2024 |
Exhibit 97.1 DODD-FRANK CLAWBACK POLICY The Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) has adopted this clawback policy (the “Policy”) as a supplement to any other clawback policies in effect now or in the future at the Company to provide for the recovery of erroneously awarded Incentive-Based Compensation from Executive Officers. This Policy shall be interpreted to compl |
|
| May 21, 2024 |
SC 13D 1 bradburya20240513sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* IGC Pharma Inc. (Name of Issuer) Common Stock, , par value $0.0001 per share (Title of Class of Securities) 45408X308 (CUSIP Number) Loo See Yuen The Center, Unit 5106-7 51st Floor 99 Queen's Road Central Ce |
|
| April 30, 2024 |
IGC Pharma, Inc. 10224 Falls Road Potomac, MD 20854 April 30, 2024 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Esq. Division of Corporation Finance Re: IGC Pharma, Inc. Registration Statement on Form S-3 (No. 333-278775) Ladies and Gentlemen: On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Reg |
|
| April 19, 2024 |
United States securities and exchange commission logo April 19, 2024 Ram Mukunda President and Chief Executive Officer IGC Pharma, Inc. |
|
| April 18, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 17, 2024 As filed with the U.S. Securities and Exchange Commission on April 17, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IGC PHARMA, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or other jurisdiction of (I.R.S. Employer incorporation or organiz |
|
| April 18, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) IGC Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Title of Each Class of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equit |
|
| April 5, 2024 |
Exhibit 99.1 IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation - Interim Data: Study Achieves Primary End Point Demonstrating Clinical and Statistically Significant Reductions Compared to Placebo in Agitation Associated with Dementia Due to Alzheimer’s Disease - Potomac, MD, March 20, 2024 – IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE Am |
|
| April 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 28, 2024 |
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock Exhibit 99.1 PRESS RELEASE ISSUED ON MARCH 26, 2024 IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock POTOMAC, March 26, 2024 - IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”), a leading asset management firm. On March 22 |
|
| March 28, 2024 |
Exhibit 10.1 FORM OF SHARE PURCHASE AGREEMENT STOCK PURCHASE AGREEMENT (this “Agreement”) dated as signed by and between IGC Pharma, Inc., a Maryland corporation (the "Company"), and Investor as identified in Exhibit B (the "Investor"). WHEREAS, the Investor desires to purchase from the Company, and the Company desires to sell and issue to the Investor, shares in IGC (the "Shares") Common Stock, p |
|
| March 22, 2024 |
Exhibit 10.1 SALES AGREEMENT A.G.P./Alliance Global Partners March 19, 2024 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: IGC Pharma, Inc., a Maryland corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of |
|
| March 22, 2024 |
Up to $6,240,510 IGC Pharma, Inc. Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To the Prospectus effective January 8, 2024) Registration No. |
|
| March 22, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 13, 2024 |
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer Exhibit 99.1 IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline Potomac, MD, March 12, 2024 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors. Mr. Lierman is currently Co-Chair of the Board of Advisors at the Institute of |
|
| March 13, 2024 |
Exhibit 10.1 IGC Board of Directors Agreement Form This Board of Directors Agreement (this “Agreement”), dated as of March, 2024 is between IGC Pharma, Inc., a corporation organized under the laws of Maryland, (“IGC or the “Company”) and , an individual, with a principal address at (“Director”). BACKGROUND IGC desires to have the benefit of Director’s knowledge and experience, and Director desires |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specifie |
|
| January 31, 2024 |
Up to $5,309,602 IGC Pharma, Inc. Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To the Prospectus effective January 8, 2024) Registration No. |
|
| January 4, 2024 |
United States securities and exchange commission logo January 4, 2024 Ram Mukunda President and Chief Executive Officer IGC Pharma, Inc. |
|
| January 4, 2024 |
IGC Pharma, Inc. 10224 Falls Road Potomac, MD 20854 January 4, 2024 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Dickerson, Esq. Division of Corporation Finance Re: IGC Pharma, Inc. Registration Statement on Form S-3 (No. 333-276330) Ladies and Gentlemen: On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced |
|
| December 29, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) IGC Pharma, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2)(3) Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price(3)(4)(5) Fee Rate Amount of Re |
|
| December 29, 2023 |
As filed with the U.S. Securities and Exchange Commission on December 29, 2023 As filed with the U.S. Securities and Exchange Commission on December 29, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IGC PHARMA, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or other jurisdiction of (I.R.S. Employer incorporation or orga |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specifi |
|
| October 27, 2023 |
Up to $8,978,437 IGC Pharma, Inc. Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To the Prospectus effective January 4, 2021) Registration No. |
|
| October 27, 2023 |
Exhibit 10.1 IGC PHARMA, INC. COMMON STOCK SALES AGREEMENT October 27, 2022 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: IGC Pharma, Inc., a Maryland corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from |
|
| October 27, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 4, 2023 |
As filed with the Securities and Exchange Commission on October 3, 2023 As filed with the Securities and Exchange Commission on October 3, 2023 Registration No. |
|
| October 4, 2023 |
October 4, 2023 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory, Esq. Division of Corporation Finance Re: IGC Pharma, Inc. Registration Statement on Form S-3 (No. 333-274802) Ladies and Gentlemen: On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Regis |
|
| October 4, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) IGC Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Title of Each Class of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(2) Eq |
|
| October 4, 2023 |
Form of Restricted Stock Unit Agreement * Exhibit 10.2 IGC PHARMA, INC. 2018 OMNIBUS INCENTIVE PLAN Notice of restricted stock unit award Participant Name and Address: You (the “Participant”) have been granted restricted stock units (“Restricted Stock Units” or “RSUs”), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the “Notice”), the IGC Pharma, Inc. 2018 Omnibus Incentive Plan the “Plan”) and the Rest |
|
| October 3, 2023 |
United States securities and exchange commission logo October 3, 2023 Ram Mukunda Chief Executive Officer IGC Pharma, Inc. |
|
| September 29, 2023 |
As filed with the U.S. Securities and Exchange Commission on September 29, 2023 As filed with the U.S. Securities and Exchange Commission on September 29, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IGC PHARMA, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or other jurisdiction of (I.R.S. Employer incorporation or org |
|
| September 29, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) IGC Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Title of Each Class of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equit |
|
| August 21, 2023 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 21, 2023 |
IGC Announces Results of its 2023 Annual Stockholders Meeting Exhibit 99.1 IGC Announces Results of its 2023 Annual Stockholders Meeting POTOMAC, MD. (Business Wire) August 21, 2023 / IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 18, 2023 (the “Annual Meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specified in |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| July 7, 2023 |
Exhibit 99.1 PRESS RELEASE ISSUED ON JULY 7, 2023 IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research POTOMAC, MD July 7, 2023 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co., Ltd. (“O-Bank” or the |
|
| July 7, 2023 |
Subsidiaries of India Globalization Capital, Inc. Exhibit 21.1 The table below lists our subsidiaries. Subsidiaries Immediate holding company Jurisdiction of Incorporation Percentage of holding as of March 31, 2023 Percentage of holding as of March 31, 2023 IGCare, LLC IGC Maryland, USA 100 100 IGC Pharma, LLC IGC Maryland, USA 100 100 Holi Hemp, LLC IGC Maryland, USA 100 100 Sunday Seltzer, LLC IGC Maryland, USA 100 100 SAN Holdings, LLC IGC Mar |
|
| July 7, 2023 |
IGC Pharma Announces a $3 Million Private Placement of its Common Stock Exhibit 99.1 PRESS RELEASE ISSUED ON JUL 6, 2023 IGC Pharma Announces a $3 Million Private Placement of its Common Stock POTOMAC, July 6, 2023 - IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a strategic investment from four investment funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”) who is a leading asset management firm with over $2 bill |
|
| July 7, 2023 |
Exhibit 10.1 |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Fiscal Year Ended March 31, 2023. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-32830 IGC PHARMA, INC. (Exact Name of Re |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 7, 2023 |
Exhibit 10.1 FORM OF SHARE PURCHASE AGREEMENT SHARE PURCHASE AGREEMENT (this “2023 SPA”) dated as signed by and between IGC Pharma, Inc., a Maryland corporation (the “Company”), and Investor as identified in Exhibit B (the “Investor”). WHEREAS, the Investor desires to purchase from the Company, and the Company desires to sell and issue to the Investor, shares in IGC (the “Shares”) Common Stock, pa |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| May 8, 2023 |
Exhibit 10.1 2023 PFO EMPLOYMENT AGREEMENT This PFO EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 9, 2023, (the “Effective Date”), by and between collectively, IGC Pharma, Inc., (“IGC”, “Employer”, “Company”) a corporation organized under the laws of Maryland, and Claudia Grimaldi (“Executive”) on the following terms and conditions: RECITALS: A. The Employer desires to be assured |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 IGC PHARMA, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 India Globalization Capital, Inc. (Exact name of registrant as specified in its charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (C |
|
| March 21, 2023 |
Exhibit 3.1 ARTICLES OF AMENDMENT for a MARYLAND STOCK CORPORATION (1) (2) India Globalization Capital, Inc. a Maryland corporation, certifies to the State Department of Assessments and Taxation of Maryland that the charter of the corporation shall be and hereby is amended as follows: (3) The name of the corporation is changed to IGC Pharma, Inc. This amendment of the charter of the corporation ha |
|
| March 21, 2023 |
IGC Announces Rebranding, Changes Name to IGC Pharma, Inc. Exhibit 99.1 IGC Announces Rebranding, Changes Name to IGC Pharma, Inc. POTOMAC, Md., March 20, 2023 – India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the fu |
|
| March 21, 2023 |
Exhibit 3.2 AMENDMENT NO. 4 TO BYLAWS OF INDIA GLOBALIZATION CAPITAL, INC. In the Bylaws, the Corporation’s name “India Globalization Capital, Inc.” is hereby deleted each place it appears, and is replaced with the Corporation’s new name “IGC Pharma, Inc.”, which was effectuated by the filing of Articles of Amendment with the Maryland State Department of Assessments and Taxation on March 7, 2023. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of regis |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2022 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) |
|
| December 20, 2022 |
IGC Announces Updated Life Sciences Presentation Exhibit 99.2 IGC Announces Updated Life Sciences Presentation POTOMAC, Md., Dec. 20, 2022 - India Globalization Capital, Inc. (NYSE American: IGC) (?IGC? or the ?Company?), today announces that a life sciences presentation has been filed with the SEC on Form 8K and is available at https://www.sec.gov/. The presentation is also published on the Company?s website https://www.igcpharma.com, The prese |
|
| December 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) |
|
| December 20, 2022 |
IGC Life Sciences Presentation dated December 2022. Exhibit 99.1 |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of regi |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2022 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Co |
|
| September 9, 2022 |
IGC Announces Results of its 2022 Annual Stockholders Meeting Exhibit 99.1 IGC Announces Results of its 2022 Annual Stockholders Meeting POTOMAC, MD. (Business Wire) September 9, 2022 / India Globalization Capital, Inc. (?IGC? or the ?Company?) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on September 9, 2022 (the ?Annual Meeting?), all proposals as disclosed on the Definitive Proxy Statement on Sch |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registran |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Fiscal Year Ended March 31, 2022. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. |
|
| June 23, 2022 |
Subsidiaries of India Globalization Capital, Inc. Exhibit 21.1 The table below lists our subsidiaries. Subsidiaries Immediate holding company Jurisdiction of Incorporation Percentage of holding as of March 31, 2022 Percentage of holding as of March 31, 2021 IGC ? Mauritius (IGC-M) (2) IGC Mauritius 100 100 IGCare, LLC IGC Maryland, USA 100 100 IGC Pharma, LLC IGC Maryland, USA 100 100 Holi Hemp, LLC IGC Maryland, USA 100 100 Sunday Seltzer, LLC I |
|
| June 9, 2022 |
IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders Exhibit 99.1 IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders Potomac, MD, June 8, 2022 - India Globalization Capital, Inc. (the ?Company?) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (?USPTO?) issued a patent (#11,351,152) to the Company titled ?Method and Composition for Treating Seizure Disorders.? The patent is assig |
|
| June 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2022 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Com |
|
| May 12, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2022 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Com |
|
| May 12, 2022 |
EXHIBIT 10.1 [***] Certain information has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K from this document because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT BY AND BETWEEN JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (?JNCASR?), BENGALURU (?LICENSOR?) AND HAMSA BIOPHARMA INDIA PRIVATE LIMITED, DEL |
|
| April 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2022 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisdict |
|
| April 18, 2022 |
Exhibit 99.1 India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits POTOMAC, MD., April 18, 2022 (BUSINESS WIRE)- India Globalization Capital, Inc. (the ?Company?) (NYSE American: IGC) announces today that on April 13, 2022, the United States District Court for the District of Maryland entered an Order granting final approval of a settle |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commi |
|
| March 23, 2022 |
India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors Exhibit 99.1 India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors POTOMAC, MD? (BusinessWire ? March 23, 2022) ? India Globalization Capital, Inc. (NYSE American: IGC) announces that the Board has appointed Ms. Claudia Grimaldi as a non-independent Director, effective March 23, 2022. IGC now has 5 directors including a majority who are independent. Ms. Grimaldi has been |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of regis |
|
| January 18, 2022 |
India Globalization Capital Appoints Former Congressman Jim Moran to its Board of Directors Exhibit 99.1 India Globalization Capital Appoints Former Congressman Jim Moran to its Board of Directors POTOMAC, MD?(BusinessWire ? January 18, 2022) ? India Globalization Capital, Inc. (NYSE American: IGC) is excited to announce that the Board has appointed former Congressman Jim Moran (?Congressman Moran?) as an independent Director. IGC is delighted to welcome Congressman Moran to its Board of |
|
| January 18, 2022 |
IGC Board of Directors Agreement Form* Exhibit 10.1 IGC Board of Directors Agreement Form This Board of Directors Agreement (this ?Agreement?), dated as of January , 2022 is between India Globalization Capital, Inc., a corporation organized under the laws of Maryland, (?IGC or the ?Company?) and , an individual, with a principal address at (?Director?). BACKGROUND IGC desires to have the benefit of Director?s knowledge and experience, |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Com |
|
| December 23, 2021 |
As filed with the Securities and Exchange Commission on December 22, 2021 As filed with the Securities and Exchange Commission on December 22, 2021 Registration No. |
|
| December 23, 2021 |
Form of Stock Option Agreement * EXHIBIT 10.2 Award Date: INDIA GLOBALIZATION CAPITAL, INC. 2018 OMNIBUS INCENTIVE PLAN NOTICE OF STOCK OPTION AWARD Participant Name and Address: You (the ?Participant?) have been granted Options to purchase shares of Common Stock, subject to the terms and conditions of this Notice of Stock Option Award (the ?Notice?), the India Globalization Capital, Inc. 2018 Omnibus Incentive Plan the ?Plan?) a |
|
| December 23, 2021 |
EXHIBIT 10.1 INDIA GLOBALIZATION CAPITAL, INC. 2018 OMNIBUS INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Participant Name and Address: Ram Mukunda You (the ?Participant?) have been granted restricted stock units (?Restricted Stock Units? or ?RSUs?), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the ?Notice?), the India Globalization Capital, Inc. 2018 O |
|
| December 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Com |
|
| December 2, 2021 |
Exhibit 99.1 Phase 1 Clinical Trial Data Indicate IGC?s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer?s Patients POTOMAC, MD, December 2, 2021, (NYSE American: IGC), India Globalization Capital, Inc. (IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The investigational new drug, IGC-AD1, is I |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Co |
|
| November 19, 2021 |
Exhibit 10.1 2021 CEO EMPLOYMENT AGREEMENT This CEO EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of November 2018, 2021, (the ?Effective Date?), by and between collectively, India Globalization Capital, Inc., (?IGC?) a corporation organized under the laws of Maryland, ?Employer?), and Ram Mukunda (?Executive?) on the following terms and conditions: RECITALS: A. The Employer desires t |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of regi |
|
| October 29, 2021 |
2014 Employment Agreement between India Globalization Capital, Inc. and Ram Mukunda. Exhibit 10.01 2014 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of July 14, 2014 (the ?Effective Date?), by and between collectively, India Globalization Capital, Inc., (?IGC?) a corporation organized under the laws of Maryland, India Globalization Capital Mauritius, (?IGC-M? and collectively with IGC, ?Employer?), and Ram Mukunda (?Executive?) on the follow |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Com |
|
| October 15, 2021 |
IGC Announces Results of its 2021 Annual Stockholders Meeting Exhibit 99.1 IGC Announces Results of its 2021 Annual Stockholders Meeting POTOMAC, MD. (BusinessWire) October 15, 2021 / India Globalization Capital, Inc. (NYSE AMERICAN: IGC) announces that during its Annual Meeting of Shareholders scheduled for and convened on October 15, 2021, voting on all matters as disclosed on the Definitive Proxy on Form 14A filed with the SEC on September 15, 2021, were |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker 1 (a) NAME OF ISSUER (Please type or print) (b) IRS I |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 11, 2021 |
2014 Employment Agreement between India Globalization Capital, Inc. and Ram Mukunda. Exhibit 10.01 2014 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of July 14, 2014 (the ?Effective Date?), by and between collectively, India Globalization Capital, Inc., (?IGC?) a corporation organized under the laws of Maryland, India Globalization Capital Mauritius, (?IGC-M? and collectively with IGC, ?Employer?), and Ram Mukunda (?Executive?) on the follow |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registran |
|
| June 14, 2021 |
Subsidiaries of India Globalization Capital, Inc. Exhibit 21.1 The table below lists our subsidiaries. Subsidiaries Immediate holding company Jurisdiction of Incorporation Percentage of holding as of March 31, 2021 Percentage of holding as of March 31, 2020 IGC ? Mauritius (IGC-M) (2) IGC Mauritius 100 100 IGCare, LLC IGC Maryland, USA 100 100 IGC Pharma, LLC IGC Maryland, USA 100 100 Holi Hemp, LLC IGC Maryland, USA 100 100 Sunday Seltzer, LLC I |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Fiscal Year Ended March 31, 2021. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker 1 (a) NAME OF ISSUER (Please type or print) (b) IRS I |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2020 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of regis |
|
| January 22, 2021 |
As filed with the U.S. Securities and Exchange Commission on January 22, 2021 Registration No. 333-251654 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or othe |
|
| January 22, 2021 |
Amended and Restated Articles of Incorporation. Exhibit 3.1 AMENDMENT AND RESTATEMENT ARTICLES OF INCORPORATION OF INDIA GLOBALIZATION CAPITAL, INC. India Globalization Capital, Inc., a corporation organized and existing under the laws of the State of Maryland (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is India Globalization Capital, Inc. The date of filing of its original Articles of Incorporation with the |
|
| January 22, 2021 |
Exhibit 3.2 BYLAWS OF INDIA GLOBALIZATION CAPITAL, INC. ARTICLE I. OFFICES AND RECORDS Section 1.01. Registered Office. The principal office of India Globalization Capital, Inc. (the "Corporation") shall be located at such place as the Board of Directors of the Corporation may designate. Section 1.02. Other Offices. The Corporation may have such other offices, either within or without the State of |
|
| January 22, 2021 |
Exhibit 3.3 ARTICLES OF AMENDMENT OF INDIA GLOBALIZATION CAPITAL, INC. INDIA GLOBALIZATION CAPITAL, INC., a Maryland corporation, having its principal office at 4336 Montgomery Avenue, Bethesda, Maryland 20814 (hereinafter referred to as the "Corporation"), hereby certifies to the State Department of Assessments and Taxation of Maryland that: FIRST: The Charter of the Corporation be hereby amended |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Com |
|
| January 14, 2021 |
IGC Announces Results of its 2020 Annual Stockholders Meeting Exhibit 99.1 IGC Announces Results of its 2020 Annual Stockholders Meeting POTOMAC, MD. (BusinessWire) January 13, 2021 / India Globalization Capital, Inc. (NYSE AMERICAN: IGC) announces that during its Annual Meeting of Shareholders scheduled for, and convened on January 11, 2021, voting on all matters as disclosed on the Definitive Proxy on Form 14A filed with the SEC on December 8, 2020 were pa |
|
| January 13, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Com |
|
| January 13, 2021 |
Exhibit 10.1 INDIA GLOBALIZATION CAPITAL, INC. COMMON STOCK SALES AGREEMENT January 13, 2021 The Benchmark Company, LLC 150 East 58th Street, 17th Floor New York, NY 10155 Ladies and Gentlemen: India Globalization Capital, Inc., a Maryland corporation (the “Company”), confirms its agreement (this “Agreement”) with The Benchmark Company, LLC, as follows: 1. Issuance and Sale of Shares. The Company |
|
| January 13, 2021 |
Common Stock India Globalization Capital, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-251654 PROSPECTUS SUPPLEMENT (To the Prospectus effective January 4, 2021) $75,000,000 Common Stock India Globalization Capital, Inc. We have entered into an At-the-Market (ATM) Sales Agreement (the “Sales Agreement”) with The Benchmark Company, LLC (“Benchmark” or the “Manager”) relating to shares of our common stock, par value $0.0001 per sha |
|
| December 31, 2020 |
EMAIL: [email protected] DIRECT DIAL: 212.451.2234 December 31, 2020 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Scott Anderegg, Esq., Division of Corporation Finance Re: India Globalization Capital, Inc. Registration Statement on Form S-3 (No. 333-251654) Ladies and Gentlemen: On behalf of India Globalization Capital, Inc. |
|
| December 31, 2020 |
United States securities and exchange commission logo December 31, 2020 Ram Mukunda President and Chief Executive Officer India Globalization Capital, Inc. |
|
| December 31, 2020 |
United States securities and exchange commission logo December 31, 2020 Ram Mukunda President and Chief Executive Officer India Globalization Capital, Inc. |
|
| December 23, 2020 |
As filed with the U.S. Securities and Exchange Commission on December 23, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or other jurisdiction of (I.R.S. Employer inco |
|
| December 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| December 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2020 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisd |
|
| December 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker 1 (a) NAME OF ISSUER (Please type or print) (b) IRS I |
|
| November 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of regi |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| August 20, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 19, 2020 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisdic |
|
| August 20, 2020 |
< Financial Tables to Follow > Exhibit 99.1 IGC Reports Financial Results for June 30, 2020 Quarter and Prepares for Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients POTOMAC, MD, August 20, 2020 / India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended June 30, 2020, which is the first quarter of its 2021 fiscal year. Revenue was appr |
|
| August 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registran |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| August 11, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2020 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisdicti |
|
| August 11, 2020 |
Exhibit 99.1 FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patients IGC Announces FDA Removal of Clinical Hold for Multiple Ascending Dose Study of IGC-AD1, Targeting Patients Suffering from Alzheimer’s-related Dementia Potomac, Maryland, August 11, 2020/ BusinessWire / India Globalization Capital (“IGC” or the “Company”) (NYSE AMERICAN: IGC) announced today that on July 30, 20 |
|
| July 20, 2020 |
IGC Receives a Notice of Allowance from the U.S. Patent Office Exhibit 99.1 IGC Receives a Notice of Allowance from the U.S. Patent Office BETHESDA, MD. July 20, 2020 / India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) recently received a Notice of Allowance dated July 8, 2020 from the United States Patent and Trademark Office (“USPTO”) for the Company’s cannabinoid formulation for the treatment of seizures in humans and veterinary animal |
|
| July 20, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2020 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisdictio |
|
| July 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Fiscal Year Ended March 31, 2020. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. |
|
| July 13, 2020 |
Exhibit 10.02 2014 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of July 14, 2014 (the “Effective Date”), by and between collectively, India Globalization Capital, Inc., (“IGC”) a corporation organized under the laws of Maryland, India Globalization Capital Mauritius, (“IGC-M” and collectively with IGC, “Employer”), and Ram Mukunda (“Executive”) on the follow |
|
| July 13, 2020 |
Subsidiaries of India Globalization Capital, Inc. Exhibit 21.1 The table below lists our subsidiaries. Subsidiaries Immediate holding company Jurisdiction of Incorporation Percentage of holding as of March 31, 2020 Percentage of holding as of March 31, 2019 IGC – Mauritius (IGC-M) (2) IGC Mauritius 100 100 IGCare, LLC IGC Maryland, USA 100 100 IGC Pharma, LLC IGC Maryland, USA 100 100 Holi Hemp, LLC IGC Maryland, USA 100 100 Sunday Seltzer, LLC I |
|
| July 13, 2020 |
Preferability Letter from Manohar Chowdhry & Associates Exhibit 18.1 July 09, 2020 India Globalization Capital, Inc. 10224 Falls Road, Potomac, Maryland - 20854 Ladies and Gentlemen: We have been furnished with a copy of the Annual report on Form 10-K of India Globalization Capital, Inc (the “Company”) for the year ended March 31, 2020 and have read the Company’s statements contained in Note 2 to the consolidated financial statements included therein. |
|
| June 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| May 13, 2020 |
Exhibit 2.1 SHARE PURCHASE AGREEMENT BY AND AMONG India Globalization Capital Inc. EVOLVE I, INC. Jay Bohannon, individually and as Sellers’ Representative And The Individual Sellers listed on Exhibit A SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT, dated as of May 11, 2020 (this “SPA”, “Agreement”), is effective April 1, 2020, and is made and entered into by and among India Globalization |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisdictio |
|
| May 8, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2020 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisdiction |
|
| May 8, 2020 |
UNITED STATES DISTRICT COURT DISTRICT OF MARYLAND Exhibit 99.1 UNITED STATES DISTRICT COURT DISTRICT OF MARYLAND In re India Globalization Capital, Inc. Derivative Litigation Lead Case No. 1:18-cv-03698-DKC Hon. Deborah K. Chasanow Lead Case No. DKC 18-3698 This Document Relates to: All Consolidated Cases NOTICE TO CURRENT INDIA GLOBALIZATION CAPITAL, INC. SHAREHOLDERS TO: ALL OWNERS OF INDIA GLOBALIZATION CAPITAL, INC. (“IGC” OR THE “COMPANY”) C |
|
| May 8, 2020 |
Exhibit 99.2 India Globalization Capital, Inc. Announces Proposed Settlement of Three Derivative Lawsuits and Provides Notice to Shareholders POTOMAC, MD., May 7, 2020: India Globalization Capital, Inc. (the “Company”) (NYSE: IGC) announces today the proposed settlement of three derivative lawsuits pending since 2018 and 2019 and provides notice to shareholders of the settlement. As previously dis |
|
| March 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2020 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisdict |
|
| March 27, 2020 |
Exhibit 99.1 IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals India Globalization Capital, Inc. (the “Company”) (NYSE: IGC) recently received notification that on March 24, 2020, the United States Patent and Trademark Office (“USPTO”) issued a method and composition patent (#10,596,159 B2) for the Company’s cannabinoid formulat |
|
| March 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2020 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisdict |
|
| February 25, 2020 |
Form of Incentive Stock Option Agreement* Exhibit 10.2 India Globalization Capital, Inc. Incentive Stock Option Agreement This Stock Option Agreement (the ?Agreement?) is entered into and made effective as of , by and between India Globalization Capital, Inc., a Maryland corporation (the ?Company?), and (the ?Optionee?). WITNESSETH: WHEREAS, the Committee desires to encourage Optionee to provide additional services to the Company and as i |
|
| February 25, 2020 |
Form of Nonqualified Stock Option Agreement* Exhibit 10.3 India Globalization Capital, Inc. Nonqualified Stock Option Agreement This Stock Option Agreement (the ?Agreement?) is entered into and made effective as of , by and between India Globalization Capital, Inc., a Maryland corporation (the ?Company?), and (the ?Optionee?). WITNESSETH: WHEREAS, the Committee desires to encourage Optionee to provide additional services to the Company and a |
|
| February 25, 2020 |
As filed with the Securities and Exchange Commission on February 25, 2020 As filed with the Securities and Exchange Commission on February 25, 2020 Registration No. |
|
| February 10, 2020 |
IGC / India Globalization Capital, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2019 ☐ Transition report under Section 13 or 15(d) of the Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specifie |
|
| January 9, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2020 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Commission File Number: 001-32830 Maryland 20-2760393 (State or other jurisdic |
|
| December 13, 2019 |
IGC / India Globalization Capital, Inc. DEF 14A - - FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 5, 2019 |
IGC / India Globalization Capital, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 ☐ Transition report under Section 13 or 15(d) of the Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specifi |
|
| August 9, 2019 |
IGC / India Globalization Capital, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 ☐ Transition report under Section 13 or 15(d) of the Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in |
|
| June 14, 2019 |
Subsidiaries of India Globalization Capital, Inc. Exhibit 21.1 The table below lists our subsidiaries. Subsidiaries (3) Immediate holding company Jurisdiction of Incorporation Percentage of holding as of March 31, 2019 Percentage of holding as of March 31, 2018 IGC – Mauritius (IGC-M) IGC Mauritius 100 100 IGCare LLC IGC Maryland, USA 100 0 IGC Pharma LLC IGC Maryland, USA 100 0 Holi Hemp LLC IGC Maryland, USA 100 0 Techni Bharathi Private Limite |
|
| June 14, 2019 |
IGC / India Globalization Capital, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Fiscal Year Ended March 31, 2019. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. |
|
| June 14, 2019 |
Exhibit 10.03 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of June 14, 2019 (the “Effective Date”), by and between collectively, India Globalization Capital, Inc., (“IGC”, “Employer”) a corporation organized under the laws of Maryland, and Claudia Grimaldi (“Executive”), an individual residing in the State of Maryland, on the following terms and conditions: R |
|
| March 27, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2019 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Commi |
|
| March 27, 2019 |
IGC Provides Corporate Updates Exhibit 99.1 IGC Provides Corporate Updates BETHESDA, MD. March 26, 2019 / India Globalization Capital, Inc. (NYSE: IGC) announces today that, as of Wednesday, March 27, 2019, Hyalolex™, the Company’s cannabinoid-based, non-FDA approved product designed to assist in helping improve the lives of patients suffering from Alzheimer’s disease, will be available for purchase in select dispensaries in Sa |
|
| February 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2019 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Co |
|
| February 22, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2019 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Co |
|
| February 22, 2019 |
IGC Announces Successful Appeal of Delisting Proceedings and Imminent Relisting on NYSE American Exhibit 99.1 IGC Announces Successful Appeal of Delisting Proceedings and Imminent Relisting on NYSE American BETHESDA, MD. February 21, 2019 / India Globalization Capital, Inc. (NYSE American: IGC; PINK: IGCC) announced today that it has successfully challenged NYSE American’s decision to delist the common stock of the Company from trading on the Exchange under the Exchange’s appeal procedures. I |
|
| February 19, 2019 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2019 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) |
|
| February 19, 2019 |
Exhibit 99.1 India Globalization Capital Announces Extension of Expiration Date and Reduction of Exercise Price of its Publicly Traded Warrants BETHESDA, MD-(BusinessWire – February 19, 2019) – India Globalization Capital Inc. (OTC: IGCC) today announced the extension of the expiration date and reduction in the exercise price for its outstanding publicly traded warrants, which are quoted on the OT |
|
| February 12, 2019 |
IGC / India Globalization Capital, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2018 ☐ Transition report under Section 13 or 15(d) of the Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specifie |
|
| November 9, 2018 |
8-K 1 indiaglob201811098k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or ot |
|
| November 1, 2018 |
NYSE American to Suspend Trading in India Globalization Capital and Commence Delisting Proceedings Exhibit 99.1 NYSE American to Suspend Trading in India Globalization Capital and Commence Delisting Proceedings BETHESDA, MD. October 29, 2018 / India Globalization Capital, Inc. (NYSE American: IGC) announces today that it received a letter from the staff of NYSE Regulation informing the Company that it has determined to commence proceedings to delist the common stock of India Globalization Capit |
|
| November 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2018 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Com |
|
| October 16, 2018 |
IGC / India Globalization Capital, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 ☐ Transition report under Section 13 or 15(d) of the Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specifi |
|
| October 15, 2018 |
IGC / India Globalization Capital, Inc. FORM S-3 As filed with the U.S. Securities and Exchange Commission on October 15, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or other jurisdiction of (I.R.S. Employer incor |
|
| October 9, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2018 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Comm |
|
| October 9, 2018 |
IGC Files Provisional Patent to Protect IP for CBD-Infused Energy Drink Exhibit 99.1 IGC Files Provisional Patent to Protect IP for CBD-Infused Energy Drink BETHESDA, MD, October 9, 2018 – India Globalization Capital, Inc. (NYSE AMERICAN: IGC) today announced that it has filed a provisional method and composition patent application (IGC-509) with the U.S. Patent and Trademark Office (USPTO) for the treatment of fatigue and energy restoration. The filing is for a provi |
|
| October 2, 2018 |
Common Stock India Globalization Capital, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-224082 PROSPECTUS SUPPLEMENT (To the Prospectus effective May 11, 2018) $15,000,000 Common Stock India Globalization Capital, Inc. We have entered into an At-the-Market (ATM) Offering Agreement (the “Sales Agreement”) with The Benchmark Company, LLC (“Benchmark”) and ViewTrade Securities, Inc. (“ViewTrade” and together with Benchmark, the “Mana |
|
| October 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2018 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Comm |
|
| October 1, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2018 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Comm |
|
| October 1, 2018 |
Common Stock India Globalization Capital, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-224082 PROSPECTUS SUPPLEMENT (To the Prospectus effective May 11, 2018) $15,000,000 Common Stock India Globalization Capital, Inc. We have entered into an At-the-Market (ATM) Offering Agreement (the “Sales Agreement”) with The Benchmark Company, LLC (“Benchmark”) and ViewTrade Securities, Inc. (“ViewTrade” and together with Benchmark, the “Mana |
|
| October 1, 2018 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT October 1, 2018 The Benchmark Company, LLC 150 East 58th Street, 17th Floor New York, New York 10155 ViewTrade Securities, Inc. 7280 W Palmetto Park Rd. #310, Boca Raton, FL 33433 Ladies and Gentlemen: India Globalization Capital, Inc., a corporation organized under the laws of Maryland (the “Company”), confirms its agreement (this “Agreement”) with Th |
|
| September 24, 2018 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT September 22, 2018 The Benchmark Company, LLC 150 East 58th Street, 17th Floor New York, New York 10155 ViewTrade Securities, Inc. 7280 W Palmetto Park Rd. #310, Boca Raton, FL, 33433 Ladies and Gentlemen: India Globalization Capital, Inc., a corporation organized under the laws of Maryland (the “Company”), confirms its agreement (this “Agreement”) wit |
|
| September 24, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2018 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (C |
|
| September 24, 2018 |
Common Stock India Globalization Capital, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-224082 PROSPECTUS SUPPLEMENT (To the Prospectus effective May 11, 2018) $15,000,000 Common Stock India Globalization Capital, Inc. We have entered into an At-the-Market (ATM) Offering Agreement (the “Sales Agreement”) with The Benchmark Company, LLC (“Benchmark”) and ViewTrade Securities, Inc. (“ViewTrade” and together with Benchmark, the “Mana |
|
| September 22, 2018 |
Common Stock India Globalization Capital, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-201822 PROSPECTUS SUPPLEMENT (To the Prospectus Supplement Dated December 21, 2017 and the Prospectus effective April 8, 2015) $10,000,000 Common Stock India Globalization Capital, Inc. This Prospectus Supplement cancels and supersedes our prospectus supplement dated December 21, 2017, related to the At the Market Offering Agreement dated Decem |
|
| September 12, 2018 |
Exhibit 99.1 PRESS RELEASE ISSUED ON SEPTEMBER 12, 2018 India Globalization Capital Raises $1 Million in Direct Equity Investment to Support Hyalolextm Commercialization Bethesda, September 12, 2018 (BUSINESSWIRE) – India Globalization Capital, Inc. (NYSE American: IGC), a company engaged in the development and commercialization of cannabinoid-based alternative therapies for medical conditions inc |
|
| September 12, 2018 |
Form of Q2 2019 Stock Purchase Agreement. Exhibit 10.1 Q2 2019 STOCK PURCHASE AGREEMENT Q2 2019 STOCK PURCHASE AGREEMENT (this “Agreement”), dated as signed by and between India Globalization Capital, Inc., a Maryland corporation (the “Company”), and Investor as identified in Exhibit B (the “Investor”). WHEREAS, the Investor desires to purchase from the Company, and the Company desires to sell and issue to the Investor, shares in IGC (the |
|
| September 12, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2018 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (C |
|
| August 21, 2018 |
Form of Incentive Stock Option Agreement* Exhibit 10.2 India Globalization Capital, Inc. Incentive Stock Option Agreement This Stock Option Agreement (the “Agreement”) is entered into and made effective as of , by and between India Globalization Capital, Inc., a Maryland corporation (the “Company”), and (the “Optionee”). WITNESSETH: WHEREAS, the Committee desires to encourage Optionee to provide additional services to the Company and as i |
|
| August 21, 2018 |
Form of Nonqualified Stock Option Agreement* Exhibit 10.3 India Globalization Capital, Inc. Nonqualified Stock Option Agreement This Stock Option Agreement (the “Agreement”) is entered into and made effective as of , by and between India Globalization Capital, Inc., a Maryland corporation (the “Company”), and (the “Optionee”). WITNESSETH: WHEREAS, the Committee desires to encourage Optionee to provide additional services to the Company and a |
|
| August 21, 2018 |
IGC / India Globalization Capital, Inc. FORM S-8 As filed with the Securities and Exchange Commission on August 21, 2018 Registration No. |
|
| August 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2018 India Globalization Capital, Inc. (Exact Name of Registrant as Specified in Its Charter) Maryland 001-32830 20-2760393 (State or other Jurisdiction of Incorporation) (C |
|
| August 7, 2018 |
IGC Announces Results of its 2018 Annual Stockholders Meeting Exhibit 99.1 IGC Announces Results of its 2018 Annual Stockholders Meeting BETHESDA, MD. August 6, 2018 / India Globalization Capital, Inc. (NYSE AMERICAN: IGC) announces that during its Annual Meeting of Shareholders scheduled for, and convened on August 6, 2018, voting on all matters as disclosed on the Definitive Proxy on Form 14A filed with the SEC on July 6, 2018 were passed. Only stockholder |
|
| August 3, 2018 |
IGC / India Globalization Capital, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 ☐ Transition report under Section 13 or 15(d) of the Exchange Act of 1934 Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in |
|
| July 6, 2018 |
IGC / India Globalization Capital, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 21, 2018 |
Subsidiaries of India Globalization Capital, Inc. Exhibit 21.1 List of Subsidiaries Subsidiaries (3) Immediate holding company Country of Incorporation Percentage of holding as of March 31, 2018 Percentage of holding as of March 31, 2017 IGC – Mauritius (“IGC-M”) IGC Mauritius 100 100 Techni Bharathi Private Limited (“TBL”) IGC-M India 0 100 Techni Bharathi Private Limited (“TBL”) IGC India 100 0 India Mining and Trading Private Limited (“IGC-IMT |
|
| June 21, 2018 |
IGC / India Globalization Capital, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended March 31, 2018. ☐ Transition report pursuant to Section 13 or 15(d) of the Exchange Act of 1934 For the transition period from to Commission file number: 001-32830 INDIA GLOBALIZATION CAPITAL, INC. (Exact |
|
| May 15, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2018. INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland 001-32830 20-2760393 (State or other jurisdiction of incorporation) (Com |
|
| May 9, 2018 |
IGC / India Globalization Capital, Inc. S-3/A As filed with the U.S. Securities and Exchange Commission on May 9 , 2018 Registration Statement No. 333-224082 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDIA GLOBALIZATION CAPITAL, INC. (Exact name of registrant as specified in its charter) Maryland 20-2760393 (State or other jurisdi |
|
| May 9, 2018 |
IGC / India Globalization Capital, Inc. CORRESP May 9, 2018 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Heather Percival, Esq., Division of Corporation Finance Re: India Globalization Capital, Inc. Registration Statement on Form S-3 (No. 333-224082) Ladies and Gentlemen: On behalf of India Globalization Capital, Inc. (the “Company”), we enclose the Company’s request for accele |
